Literature DB >> 12907387

Development of a recombinant vaccine against Japanese encephalitis.

Rupinderjeet Kaur1, Sudhanshu Vrati.   

Abstract

Japanese encephalitis (JE) is the major form of viral encephalitis in much of the South-East Asia, India, and China. The disease is caused by a mosquito-borne virus known as Japanese encephalitis virus (JEV). The virus spreads in the form of epidemics, although several endemic areas for JEV activity are known. In recent years, JEV has spread to newer geographic locations such as Australia and Pakistan, and thus has become an important emerging virus infection in these areas. A mouse brain-derived, formalin-inactivated vaccine is available for immunization against JE. Because the formalin-inactivated JEV vaccine has limitations in terms of safety, availability, and cost, attempts are being made to develop improved vaccine using the recombinant DNA technology. This article reviews various attempts in this direction and summarizes the latest developments such as the recombinant yellow fever virus- or the plasmid DNA-based JEV vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907387     DOI: 10.1080/13550280390218454

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  69 in total

1.  Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies.

Authors:  J Kimura-Kuroda; K Yasui
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

2.  Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.

Authors:  E Konishi; A Fujii; P W Mason
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

4.  Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

Authors:  T J Chambers; A Nestorowicz; P W Mason; C M Rice
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.

Authors:  H M Murthy; K Judge; L DeLucas; R Padmanabhan
Journal:  J Mol Biol       Date:  2000-08-25       Impact factor: 5.469

6.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3.

Authors:  Greg Bartelma; R Padmanabhan
Journal:  Virology       Date:  2002-07-20       Impact factor: 3.616

8.  A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione-S-transferase elicit neutralizing antibody in mice.

Authors:  S A Seif; K Morita; A Igarashi
Journal:  Virus Res       Date:  1996-07       Impact factor: 3.303

9.  Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.

Authors:  E Konishi; S Pincus; E Paoletti; R E Shope; P W Wason
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

10.  Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus.

Authors:  E Konishi; S Pincus; B A Fonseca; R E Shope; E Paoletti; P W Mason
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

View more
  19 in total

1.  Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus.

Authors:  Sahil Kulkarni; Sandeepan Mukherjee; Krishna Mohan Padmanabha Das; Kaushiki Prabhudesai; Nupur Deshpande; Sushant Karnik; Abhay S Chowdhary; Usha Padmanabhan
Journal:  Virusdisease       Date:  2017-05-25

Review 2.  Japanese Encephalitis : Is Routine Immunization Required?

Authors:  Zile Singh; V K Agarwal
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Anticipating Emerging Mosquito-borne Flaviviruses in the USA: What Comes after Zika?

Authors:  Michelle V Evans; Courtney C Murdock; John M Drake
Journal:  Trends Parasitol       Date:  2018-03-15

4.  Development of a vaccine to prevent Japanese encephalitis: a brief review.

Authors:  Viroj Wiwanitkit
Journal:  Int J Gen Med       Date:  2009-12-29

5.  Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system.

Authors:  Kallol Dutta; Debapriya Ghosh; Anirban Basu
Journal:  J Neuroimmune Pharmacol       Date:  2009-05-12       Impact factor: 4.147

6.  Bellary, India achieves negligible case fatality due to Japanese encephalitis despite no vaccination: an outbreak investigation in 2004.

Authors:  Neeru Gupta; Kunal Chatterjee; Somenath Karmakar; S K Jain; S Venkatesh; Shiv Lal
Journal:  Indian J Pediatr       Date:  2008-01       Impact factor: 1.967

Review 7.  Control of Japanese encephalitis in India: a reality.

Authors:  Lalitha Kabilan
Journal:  Indian J Pediatr       Date:  2004-08       Impact factor: 5.319

8.  Japanese encephalitis-a pathological and clinical perspective.

Authors:  Debapriya Ghosh; Anirban Basu
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

9.  Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response.

Authors:  Fengjuan Wang; Xiuli Feng; Qisheng Zheng; Hongyan Hou; Ruibing Cao; Bin Zhou; Qingtao Liu; Xiaodong Liu; Ran Pang; Jin Zhao; Wenlei Deng; Puyan Chen
Journal:  Virol J       Date:  2012-09-17       Impact factor: 4.099

10.  Antiviral Activity of Isatis indigotica Extract and Its Derived Indirubin against Japanese Encephalitis Virus.

Authors:  Shu-Jen Chang; Yi-Chih Chang; Kai-Zen Lu; Yi-Yun Tsou; Cheng-Wen Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-17       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.